pISSN 1226-6051
eISSN 2508-786X

Table. 3.

Table. 3.

Meta-analyses of laboratory characteristics

Study N (%)

Lymphocytopeniaa High CRPb High PCTc
Lu X, et al.3 6 (3.5) 33 (19.3) 105 (61.4)
Su L, et al.11 0 0 3 (33.3)
Zhou Y, et al.12 0 2 (22.2) N/R
Wei M, et al.13 N/R N/R N/R
Li W, et al.14 N/R 1 (20.0) N/R
Zheng F, et al.15 N/R N/R N/R
Cai J, et al.16 0 3 (30.0) 7 (70.0)
Liu H, et al.17 N/R N/R N/R
Liu W, et al.18 4 (66.7) 5 (83.3) N/R
Qiu H, et al.19 11 (30.6) 1 (2.8) 6 (16.7)
Wang D, et al.20 2 (6.5) 3 (9.7) 1 (3.2)
Liu M, et al.21 0 N/R N/R
Meta-analyses outcomes (random-effects model)
Patients with positive outcome/included patients (n) 23/277 48/277 122/257
Proportion (%) 11.4 18.6 32.4
95% CI 3.8-29.5 9.7-32.6 11.8-63.2
I2 statistics (%) 78 55 88
τ2 1.9154 0.5433 1.7262
P-value <0.01 0.03 <0.01
P-value of Egger’s test 0.7273 0.9333 0.1896

CRP, c-reactive protein; N/R, not reported; PCT, procalcitonin

a Lymophocytopenia was defined as lower than 1.2x109 /L.

b High CRP was defined as higher than 10 mg/L.

c High PCT was defined as higher than 0.46 ng/mL.

Korean J Clin Pharm 2020;30:270-8 https://doi.org/10.24304/kjcp.2020.30.4.270
© 2020 Korean J Clin Pharm